jj fish funds casino Zhong Moyan, a well-respected figure in the town, had been serving as the principal of the elementary school for over a decade. During her tenure, she was credited with improving the academic performance and overall reputation of the school. However, her downfall came swiftly when an investigation revealed that she had been engaging in corrupt activities behind the scenes.One artificial intelligence (AI) stock that has received a lot of buzz is SoundHound AI ( SOUN 18.20% ) . While the reasons for the hype are numerous, they don't overshadow the fact that SoundHound AI is growing rapidly with a bullish outlook in 2025. As a result, the stock could continue to record serious gains, and investors may want to keep this stock on their radar heading into 2025. SoundHound is improving voice recognition in multiple industries SoundHound AI does pretty much what its name suggests: It incorporates AI with audio recognition. Integrating AI models with voice prompts has long been done; just take a look at the various car, home, or phone assistants. However, the recognition of voice inputs has always been OK at best, and the response quality also varied. The company's platform delivers strong advancements in this technology, and it has already seen widespread adoption in some fields. One area it has seen success in is restaurant order automation. Whether it's over the phone or in a drive-thru, SoundHound has a product that can outperform humans in terms of speed and accuracy. Another area SoundHound has seen growth is the automobile market. Specifically, through its partnership with Stellantis , SoundHound has rolled out generative AI-powered chatbots that are far more capable than the run-of-the-mill vehicle assistants most vehicles were previously equipped with. This technology hasn't made it to the U.S. yet, but it has been integrated into newer Stellantis vehicles in Europe and Japan. There are countless more uses for SoundHound's technology, and the opportunities form the foundation of an attractive investment. 2025 is set to be an amazing year In the third quarter, SoundHound's revenue rose an impressive 89% year over year to $25.1 million. A year ago, 90% of revenue came from the automotive industry, but in the latest quarter, the largest sector was only 25% as restaurants, financial services, insurance, and healthcare have all increased their share. SoundHound isn't profitable as it's still in the early stages of growth. Still, investors should know its operating loss was $33.8 million for the quarter, meaning expenses more than doubled what the company generated in revenue. That said, unless SoundHound's growth falls off substantially, this loss is not yet a major concern. Fortunately, management is guiding for full-year 2024 revenue of $82 million to $85 million, up more than 75% from the previous year. And in 2025, management expects revenue to land between $155 million and $175 million, thanks in part to its acquisition of Amelia, an enterprise voice AI company. As a cherry on top, management expects to deliver positive earnings before interest, taxes, depreciation and amortization ( EBITDA ) by the end of 2025. I have little doubt the stock will soar if management can deliver on that bullish guidance. Because SoundHound AI is unprofitable, a popular valuation metric to consider is the price-to-sales (P/S) ratio. The stock trades at a pricey 29 times sales. Data by YCharts . However, that valuation is not completely out of the ordinary, especially for the market's top AI stocks. Palantir , one of the S&P 500 's best performers in 2024, trades at more than 55 times sales while growing revenue at a less impressive pace than SoundHound AI. That said, Palantir is also a much larger and more profitable business. In the end, investors should be aware of the risk that comes with SoundHound's premium valuation. Shareholders' expectations are sky high. Meanwhile, many of its business relationships are rather new and still susceptible to disruption. As a result, investors need to ensure their position sizing is representative of the risk associated with a volatile growth stock. If SoundHound can meet its financial targets, continue to grow its customer base, and further expand into new industries, it has the potential to extend its winning streak. In fact, I wouldn't be surprised if SoundHound AI proves to be one of 2025's best-performing stocks .

The "Final Destination" series has always been known for its unique premise - a group of individuals narrowly escape a tragic disaster thanks to a premonition, only to realize that death is now coming for them in the form of freak accidents that cannot be avoided. The films have captivated audiences with their blend of horror, suspense, and supernatural elements, making them a beloved cult favorite among fans of the genre.MELBOURNE, Australia and INDIANAPOLIS , Dec. 30, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX250-CDx (Zircaix®[1], 89 Zr- girentuximab) kidney cancer imaging[2]. TLX250-CDx is an investigational PET[3] drug product for the non-invasive diagnosis and characterisation of clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer. If approved, TLX250-CDx will be the first and only targeted PET agent specifically for kidney cancer to be commercially available in the U.S., further building on Telix's successful urology imaging franchise. The FDA is expected to advise the PDUFA[4] goal date following the 60-day administrative review of the application. Kevin Richardson , Chief Executive Officer, Precision Medicine at Telix, stated, "We are pleased to be progressing the BLA for TLX250-CDx, which has been granted Breakthrough designation, and may therefore be eligible for priority review. Telix continues to target a full U.S. commercial launch in 2025 addressing a major unmet medical need for patients with suspected ccRCC." About TLX250-CDx TLX250-CDx (Zircaix® 1 ) is an investigational PET agent that is under development for the diagnosis and characterisation of ccRCC. Telix's pivotal Phase III ZIRCON trial (ClinicalTrials.gov ID: NCT03849118 ) evaluating TLX250-CDx in 300 patients, of whom 284 were evaluable, met all primary and secondary endpoints, including showing 86% sensitivity and 87% specificity and a 93% positive-predictive value for ccRCC across three independent radiology readers[5]. Telix believes this demonstrated the ability of TLX250-CDx to reliably detect the clear cell phenotype and provide an accurate, non-invasive method for diagnosing and characterising ccRCC. Confidence intervals exceeded expectations amongst all three readers, showing evidence of high accuracy and consistency of interpretation. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia , with international operations in the United States , Europe ( Belgium and Switzerland ), and Japan . Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX). Telix's lead imaging product, gallium-68 ( 68 Ga) gozetotide injection (also known as 68 Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA)[6], by the Australian Therapeutic Goods Administration (TGA) [7], and by Health Canada [8] . No other Telix product has received a marketing authorisation in any jurisdiction. Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn . Telix Investor Relations Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Investor Relations and Corporate Communications Email: kyahn.williamson@telixpharma.com This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board. Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States . The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Illuccix® and Zircaix® 1 names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.

In addition to the physical changes at the bus stations, there have also been improvements to the bus services themselves. New routes have been introduced to connect previously underserved areas, making it easier for residents to access key locations such as shopping centers, schools, and hospitals. The frequency of buses on popular routes has been increased during peak hours to reduce waiting times and congestion.Flag football uses talent camps to uncover new stars

Molson Coors Beverage Co. Cl B stock rises Tuesday, outperforms market

French midfielder Paul Pogba's contract with Manchester United will also be up for renewal next year. Known for his creativity and vision on the pitch, Pogba has been a key player for the Red Devils.NGOs to face more checks along foreign funding routeThe buzz around the match wasn't just limited to online discussions. Local businesses in the small town where the fourth-tier team was based saw a surge in interest and support. Merchandise sales skyrocketed as fans scrambled to get their hands on scarves, jerseys, and other memorabilia to show their allegiance. Bars and restaurants in the area also made preparations to host special viewing parties, expecting a full house of enthusiastic spectators on match day.

In a thrilling announcement that has sparked excitement among fans of Chinese animated films, it was officially confirmed that "Nezha 2: The Mischievous Child Causes Havoc at Sea" is set to premiere on Chinese New Year 2025. Following in the footsteps of its predecessor, the highly anticipated sequel promises to deliver a blend of action, adventure, and mythology that captivated audiences worldwide.In a rapidly changing world where technology and industries evolve at breakneck speed, having a strong foundation of experience can be a critical asset. While younger candidates may excel in certain areas, such as embracing new technologies or trends, older professionals bring a depth of understanding and a proven track record that can set them apart.

The Three Major Indices Opened Higher, ChiNext Index Surged by 4.88%, A-shares Soared

AP News Summary at 4:50 p.m. ESTPakistani police arrest thousands of Imran Khan supporters ahead of rally in the capital

Founded in 1981, NCI has a long history of providing comprehensive insurance solutions to individuals and businesses. Over the years, the company has built a strong reputation for its professionalism, reliability, and integrity. With a focus on customer satisfaction, NCI has been able to develop long-lasting relationships with its clients, earning their trust and loyalty.In addition to its attractive location and development potential, the land parcel in Fengtai District also benefits from a favorable policy environment that supports sustainable and innovative urban development. With the Chinese government's push for urban renewal and the promotion of green and smart city initiatives, the winning bidder will have the opportunity to showcase their commitment to sustainable development and urban planning.